None listed
Conditions
Interventions
Intervention1: Quadrivalent Inactivated Influenza Vaccine, No Preservative: 0.25 mL, Intramuscular (2 injections 28 days apart for participants aged 6 to 35 months)
others 0.5 mL, Intramuscular
Control Intervention1: Not Applicable: Not Applicable
Sponsors
Sanofi Pasteur SA
Sanofi Pasteur India Private Limited
Eligibility
Inclusion criteria
Inclusion criteria: - Aged 6 months or older on the day of inclusion - For subjects aged 6 to 35 months only: born at full term of pregnancy (>=37 weeks) or birth weight >=2.5 kg or both - Informed consent form has been signed and dated by the subjects / subjectsâ?? parent(s) or another legally acceptable representative and by an independent witness, if required by local regulations. For subjects aged 7 to 17 years of age, assent form has been signed and dated by the subject - Subject / subjectsâ?? parent/legally acceptable representative are able to attend all scheduled visits and to comply with all trial procedures.
Exclusion criteria
Exclusion criteria: • For subjects aged 9 years or older only: Subject is pregnant, or lactating, or of childbearing potential (to be considered of non-childbearing potential, a female must be pre-menarche or post-menopausal for at least 1 year, surgically sterile, or using an effective method of contraception or abstinence from at least 4 weeks prior to vaccination and until at least 4 weeks after vaccination) •Participation at the time of study enrollment (or in the 4 weeks preceding the first trial vaccination) or planned participation during the present trial period in another clinical trial investigating a vaccine, drug, medical device, or medical procedure •Receipt of any vaccine in the 4 weeks preceding the first trial vaccination or planned receipt of any vaccine in the 4 weeks following any trial vaccination (except oral poliomyelitis vaccine [OPV] received during national immunization days) •For subjects aged 9 years or older only: previous vaccination against influenza (in the previous 9 months) with any influenza vaccine. •For subjects aged 6 months to 8 years only: previous priming with any influenza vaccine (i.e., subjects who received 2 doses for at least 1 previous influenza season) •Receipt of immune globulins, blood or blood-derived products in the past 3 months •Known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy, such as anti-cancer chemotherapy or radiation therapy, within the preceding 6 months; or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months) •Self-reported history of seropositivity for Human Immunodeficiency Virus (HIV), Hepatitis B, or Hepatitis C, after questioning •Known systemic hypersensitivity to any of the vaccine components, or history of a life-threatening reaction to the vaccine(s) used in the trial or to a vaccine containing any of the same substances •Self-reported thrombocytopenia or as reported by the parent/legally acceptable representative, contraindicating intramuscular (IM) vaccination •Bleeding disorder, or receipt of anticoagulants in the 3 weeks preceding inclusion, contraindicating IM vaccination •Deprived of freedom by an administrative or court order, or in an emergency setting, or hospitalized involuntarily •For subjects aged 9 years or older only: current alcohol abuse or drug addiction •Chronic illness that, in the opinion of the investigator, is at a stage where it might interfere with trial conduct or completion •Moderate or severe acute illness/infection (according to investigator judgment) on the day of vaccination or febrile illness (axillary temperature >= 38.0°C). A prospective subject should not be included in the study until the condition has resolved or the febrile event has subsided •Identified as an Investigator or employee of the Investigator or study center with direct involvement in the proposed study, or identified as an immediate family member (i.e., parent, spouse, natural or adopted child) of the Investigator or employee with direct involvement in the proposed study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Geometric mean titers of antibodies to vaccine antigens pre- and post-vaccination with Fluzone Quadrivalent vaccineTimepoint: Day 0 (pre-vaccination) and Day 28 post-vaccination | — |
Secondary
| Measure | Time frame |
|---|---|
| Number of participants reporting solicited injection site and systemic events and unsolicited adverse events following vaccination with Quadrivalent Inactivated Influenza VaccineTimepoint: Day 0 up to 1 month (age 9 years and older) 2 months (Age 6 months to 8 years old participants) post vaccination | — |
Countries
India
Contacts
Public ContactDr Sujatha Shetty
Sanofi Pasteur India Private Limited
Outcome results
None listed